These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 7648835)
41. In-vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin. Gould IM; Milne K J Antimicrob Chemother; 1997 Jan; 39(1):53-61. PubMed ID: 9044028 [TBL] [Abstract][Full Text] [Related]
42. The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria. Mehtar S; Drabu YJ; Blakemore PH J Antimicrob Chemother; 1990 Jun; 25(6):915-9. PubMed ID: 2164513 [TBL] [Abstract][Full Text] [Related]
43. Clinical use of beta-lactamase inhibitors in combination with extended-spectrum penicillins. Jones RN Am J Health Syst Pharm; 1995 Mar; 52(6 Suppl 2):S29-33. PubMed ID: 7606587 [TBL] [Abstract][Full Text] [Related]
44. Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital. Platsouka E; Zissis NP; Constantoulaki S; Paniara O J Chemother; 1997 Oct; 9(5):336-40. PubMed ID: 9373788 [TBL] [Abstract][Full Text] [Related]
45. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). Sader HS; Farrell DJ; Flamm RK; Jones RN J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763 [TBL] [Abstract][Full Text] [Related]
46. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases. Gatermann S; Marre R Infection; 1991; 19(2):106-9. PubMed ID: 1646771 [TBL] [Abstract][Full Text] [Related]
47. Susceptibility of beta-lactamase-producing enterococci to piperacillin with tazobactam. Okhuysen PC; Singh KV; Murray BE Diagn Microbiol Infect Dis; 1993 Oct; 17(3):219-24. PubMed ID: 8112031 [TBL] [Abstract][Full Text] [Related]
48. Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Bryson HM; Brogden RN Drugs; 1994 Mar; 47(3):506-35. PubMed ID: 7514977 [TBL] [Abstract][Full Text] [Related]
49. In vitro activity of YTR 830. Jacobs MR; Aronoff SC; Appelbaum PC; Yamabe S J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029 [TBL] [Abstract][Full Text] [Related]
50. Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam. Mokaddas EM; Sanyal SC J Chemother; 1999 Apr; 11(2):93-6. PubMed ID: 10326738 [TBL] [Abstract][Full Text] [Related]
51. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility. Shortridge D; Pfaller MA; Castanheira M; Flamm RK Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729 [TBL] [Abstract][Full Text] [Related]
52. Comparative activities of piperacillin and tazobactam against clinical isolates of Legionella spp. Collins LA; Wennersten CB; Ferraro MJ; Moellering RC; Eliopoulos GM Antimicrob Agents Chemother; 1994 Jan; 38(1):144-6. PubMed ID: 8141570 [TBL] [Abstract][Full Text] [Related]
53. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579 [TBL] [Abstract][Full Text] [Related]
54. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase. Knapp CC; Sierra-Madero J; Washington JA Diagn Microbiol Infect Dis; 1989; 12(6):511-5. PubMed ID: 2560423 [TBL] [Abstract][Full Text] [Related]
55. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015). Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143 [TBL] [Abstract][Full Text] [Related]